{
    "organizations": [],
    "uuid": "433ed8330d977b8326de4e701447c266fe0ea81b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-agtc-doses-first-patient-in-phase/brief-agtc-doses-first-patient-in-phase-1-2-clinical-study-of-gene-therapy-for-treatment-of-x-linked-retinitis-pigmentosa-idUSFWN1RV0DQ",
    "ord_in_thread": 0,
    "title": "BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News  11 AM / Updated 14 minutes ago BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa Reuters Staff 1 Min Read \nApril 18 (Reuters) - Applied Genetic Technologies Corp : \n* AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:",
    "published": "2018-04-18T14:10:00.000+03:00",
    "crawled": "2018-04-18T14:33:45.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "updated",
        "minute",
        "ago",
        "dos",
        "first",
        "patient",
        "phase",
        "clinical",
        "study",
        "gene",
        "therapy",
        "treatment",
        "retinitis",
        "pigmentosa",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "applied",
        "genetic",
        "technology",
        "corp",
        "agtc",
        "dos",
        "first",
        "patient",
        "phase",
        "clinical",
        "study",
        "gene",
        "therapy",
        "treatment",
        "retinitis",
        "pigmentosa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}